未知生产厂商
Eritoran is a structural analogue of the lipid A portion of lipopolysaccharide (LPS). It is being developed by Eisai Research Institute of Boston for the treatment of severe sepsis.
Eritoran is a structural analogue of the lipid A portion of lipopolysaccharide (LPS). It is being developed by Eisai Research Institute of Boston for the treatment of severe sepsis.
Eritoran is a toll-like receptor 4 inhibitor.
Investigated for use/treatment in sepsis and septicemia.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
